Kidswell Bio (4584.T) Stock Price

Kidswell Bio Price

CLOSED
160.00
​
Market closed

Revenue has compounded at 21.4% per year over the past 18 years to 6.59 B JPY. Kidswell Bio's net margin stands at -6.3%, up from -35.1% several years earlier. Analysts set a median price target of 459.00 JPY, implying 186.9% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.

Kidswell Bio stock price

Access this data via the Eulerpool API

Kidswell Bio business model & stock analysis

Kidswell Bio Corp. engages in the research and development of biopharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 41 full-time employees. The company went IPO on 2012-11-30. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.

Frequently asked questions about Kidswell Bio

Analysts currently set an average price target of 459.00 JPY for the Kidswell Bio stock (median: 459.00 JPY), implying +186.9 % versus the latest price. The consensus is based on 5 analyst ratings.

5 analysts currently rate the Kidswell Bio stock: 4 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Kidswell Bio share trades at 0.90 EUR (160.00 JPY).

The revenue of Kidswell Bio is 6.59 B JPY. This figure is based on current financial data and reflects the company's business performance.

The profit of Kidswell Bio is -413.99 M JPY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Kidswell Bio is currently -19.61. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Kidswell Bio stock.

The price-to-sales ratio (P/S) of Kidswell Bio is currently 1.23. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Kidswell Bio stock.

The Eulerpool Quality Score for Kidswell Bio is 3/10.

The ISIN of Kidswell Bio is JP3386460004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Kidswell Bio is 4584.T. The ticker symbol is used to trade Kidswell Bio shares on the stock exchange.

Fair ValueTerminal
158.40 JPY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
160.73 M JPY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
JPY
Initial public offering
Nov 30, 2012
ISIN
JP3386460004
Cusip
J1770Q108
Market capitalization
7.94 B JPYMid Cap
52-Week Range
PEG
-1.02
P/E ratio
P/Ee 2027
8.29
P/Ee 2028
5.41
P/Ee 2029
4.89
P/S
P/Se
1.65
EV/EBIT
—
P/B Ratio
4.80
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-9.85 %
Last updated Oct 11, 2026, 11:22 AM

Kidswell Bio Peer Group

Kidswell Bio FIGI

4584:JP · BBG003LHRRJ34584:JT · BBG003LHRRM94584:JJ · BBG003LHRS654584:JE · BBG003LHRSC84584:JI · BBG003LHRSF54584:JU · BBG003LHRSH34584:JW · BBG00875LD294584:JV · BBG0193RCVB2